Home • Search • Translate
From Wikipedia, the free encyclopedia
3,5-Diiodothyronine
Names
IUPAC name
2-Amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
Identifiers
3D model ( JSmol)
ChemSpider
MeSH 3,5-diiodothyronine
PubChem CID
UNII
  • InChI=1S/C15H13I2NO4/c16-11-5-8(7-13(18)15(20)21)6-12(17)14(11)22-10-3-1-9(19)2-4-10/h1-6,13,19H,7,18H2,(H,20,21)
    Key: ZHSOTLOTTDYIIK-UHFFFAOYSA-N
  • C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I
  • C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I
Properties
C15H13I2NO4
Molar mass 525.081 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

3,5-Diiodothyronine (3,5-T2) is an active thyroid hormone within the class of iodothyronines. It has two iodine atoms at positions 3 and 5 of its inner ring.

Biological effects

3,5-T2 is an active thyroid hormone. It stimulates the TR-beta receptor for thyroid hormones and thus increases energy expenditure. [1] [2] It has agonistic (thyromimetic) effects at myocardial tissue and pituitary, which results in 3,5-T2 suppressing TSH release. [3] [4] 3,5-T2 is an allosteric regulator of the cytochrome c oxidase, the complex IV of the electron transport chain. It increases its activity by preventing the interaction of adenosine triphosphate (ATP) as an allosteric inhibitor. [5]

Clinical significance

In nonthyroidal illness syndrome 3,5-T2 concentrations are increased. [6] [7] [8] [9] This could explain why patients with low T3 syndrome don't benefit from substitution therapy with thyroid hormones. [7]

References

  1. ^ Goglia F (2014). "The effects of 3,5-diiodothyronine on energy balance". Frontiers in Physiology. 5: 528. doi: 10.3389/fphys.2014.00528. PMC  4292545. PMID  25628573.
  2. ^ Lombardi A, Senese R, De Matteis R, Busiello RA, Cioffi F, Goglia F, Lanni A (2015). "3,5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats". PLOS ONE. 10 (2): e0116498. Bibcode: 2015PLoSO..1016498L. doi: 10.1371/journal.pone.0116498. PMC  4319745. PMID  25658324.
  3. ^ Padron AS, Neto RA, Pantaleão TU, de Souza dos Santos MC, Araujo RL, de Andrade BM, da Silva Leandro M, de Castro JP, Ferreira AC, de Carvalho DP (Jun 2014). "Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues". The Journal of Endocrinology. 221 (3): 415–27. doi: 10.1530/JOE-13-0502. PMC  4045230. PMID  24692290.
  4. ^ Jonas W, Lietzow J, Wohlgemuth F, Hoefig CS, Wiedmer P, Schweizer U, Köhrle J, Schürmann A (Jan 2015). "3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice". Endocrinology. 156 (1): 389–99. doi: 10.1210/en.2014-1604. PMC  4272399. PMID  25322465.
  5. ^ Arnold S.; Goglia F.; Kadenbach B. (1998). "3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP". Eur. J. Biochem. 252 (2): 325–330. doi: 10.1046/j.1432-1327.1998.2520325.x. PMID  9523704.
  6. ^ Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Gräf KJ, Stoltenburg-Didinger G, Eravci M, Prengel H, Brödel O, Finke R, Baumgartner A (May 1997). "Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors". The Journal of Clinical Endocrinology and Metabolism. 82 (5): 1535–42. doi: 10.1210/jcem.82.5.3939. PMID  9141546.
  7. ^ a b Dietrich JW, Müller P, Schiedat F, Schlömicher M, Strauch J, Chatzitomaris A, Klein HH, Mügge A, Köhrle J, Rijntjes E, Lehmphul I (Jun 2015). "Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling". European Thyroid Journal. 4 (2): 129–37. doi: 10.1159/000381543. PMC  4521060. PMID  26279999.
  8. ^ Langouche, L; Lehmphul, I; Perre, SV; Köhrle, J; Van den Berghe, G (December 2016). "Circulating 3-T1AM and 3,5-T2 in Critically Ill Patients: A Cross-Sectional Observational Study". Thyroid. 26 (12): 1674–1680. doi: 10.1089/thy.2016.0214. PMID  27676423.
  9. ^ Chatzitomaris, Apostolos; Hoermann, Rudolf; Midgley, John E.; Hering, Steffen; Urban, Aline; Dietrich, Barbara; Abood, Assjana; Klein, Harald H.; Dietrich, Johannes W. (20 July 2017). "Thyroid Allostasis–Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming". Frontiers in Endocrinology. 8: 163. doi: 10.3389/fendo.2017.00163. PMC  5517413. PMID  28775711.

External links

Retrieved from " https://en.wikipedia.org/?title=3,5-Diiodothyronine&oldid=1230833112"
From Wikipedia, the free encyclopedia
3,5-Diiodothyronine
Names
IUPAC name
2-Amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
Identifiers
3D model ( JSmol)
ChemSpider
MeSH 3,5-diiodothyronine
PubChem CID
UNII
  • InChI=1S/C15H13I2NO4/c16-11-5-8(7-13(18)15(20)21)6-12(17)14(11)22-10-3-1-9(19)2-4-10/h1-6,13,19H,7,18H2,(H,20,21)
    Key: ZHSOTLOTTDYIIK-UHFFFAOYSA-N
  • C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I
  • C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I
Properties
C15H13I2NO4
Molar mass 525.081 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

3,5-Diiodothyronine (3,5-T2) is an active thyroid hormone within the class of iodothyronines. It has two iodine atoms at positions 3 and 5 of its inner ring.

Biological effects

3,5-T2 is an active thyroid hormone. It stimulates the TR-beta receptor for thyroid hormones and thus increases energy expenditure. [1] [2] It has agonistic (thyromimetic) effects at myocardial tissue and pituitary, which results in 3,5-T2 suppressing TSH release. [3] [4] 3,5-T2 is an allosteric regulator of the cytochrome c oxidase, the complex IV of the electron transport chain. It increases its activity by preventing the interaction of adenosine triphosphate (ATP) as an allosteric inhibitor. [5]

Clinical significance

In nonthyroidal illness syndrome 3,5-T2 concentrations are increased. [6] [7] [8] [9] This could explain why patients with low T3 syndrome don't benefit from substitution therapy with thyroid hormones. [7]

References

  1. ^ Goglia F (2014). "The effects of 3,5-diiodothyronine on energy balance". Frontiers in Physiology. 5: 528. doi: 10.3389/fphys.2014.00528. PMC  4292545. PMID  25628573.
  2. ^ Lombardi A, Senese R, De Matteis R, Busiello RA, Cioffi F, Goglia F, Lanni A (2015). "3,5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats". PLOS ONE. 10 (2): e0116498. Bibcode: 2015PLoSO..1016498L. doi: 10.1371/journal.pone.0116498. PMC  4319745. PMID  25658324.
  3. ^ Padron AS, Neto RA, Pantaleão TU, de Souza dos Santos MC, Araujo RL, de Andrade BM, da Silva Leandro M, de Castro JP, Ferreira AC, de Carvalho DP (Jun 2014). "Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues". The Journal of Endocrinology. 221 (3): 415–27. doi: 10.1530/JOE-13-0502. PMC  4045230. PMID  24692290.
  4. ^ Jonas W, Lietzow J, Wohlgemuth F, Hoefig CS, Wiedmer P, Schweizer U, Köhrle J, Schürmann A (Jan 2015). "3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice". Endocrinology. 156 (1): 389–99. doi: 10.1210/en.2014-1604. PMC  4272399. PMID  25322465.
  5. ^ Arnold S.; Goglia F.; Kadenbach B. (1998). "3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP". Eur. J. Biochem. 252 (2): 325–330. doi: 10.1046/j.1432-1327.1998.2520325.x. PMID  9523704.
  6. ^ Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Gräf KJ, Stoltenburg-Didinger G, Eravci M, Prengel H, Brödel O, Finke R, Baumgartner A (May 1997). "Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors". The Journal of Clinical Endocrinology and Metabolism. 82 (5): 1535–42. doi: 10.1210/jcem.82.5.3939. PMID  9141546.
  7. ^ a b Dietrich JW, Müller P, Schiedat F, Schlömicher M, Strauch J, Chatzitomaris A, Klein HH, Mügge A, Köhrle J, Rijntjes E, Lehmphul I (Jun 2015). "Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling". European Thyroid Journal. 4 (2): 129–37. doi: 10.1159/000381543. PMC  4521060. PMID  26279999.
  8. ^ Langouche, L; Lehmphul, I; Perre, SV; Köhrle, J; Van den Berghe, G (December 2016). "Circulating 3-T1AM and 3,5-T2 in Critically Ill Patients: A Cross-Sectional Observational Study". Thyroid. 26 (12): 1674–1680. doi: 10.1089/thy.2016.0214. PMID  27676423.
  9. ^ Chatzitomaris, Apostolos; Hoermann, Rudolf; Midgley, John E.; Hering, Steffen; Urban, Aline; Dietrich, Barbara; Abood, Assjana; Klein, Harald H.; Dietrich, Johannes W. (20 July 2017). "Thyroid Allostasis–Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming". Frontiers in Endocrinology. 8: 163. doi: 10.3389/fendo.2017.00163. PMC  5517413. PMID  28775711.

External links

Retrieved from " https://en.wikipedia.org/?title=3,5-Diiodothyronine&oldid=1230833112"

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook




Top Of Page

Home • Search • Translate

© CSE